Applicants: Salvador Puig et al.

Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 7 of 8

REMARKS

Claims 1-17 were pending in the subject application. Applicants note that new claims 14-17 were submitted on September 30, 2008 in a Second Preliminary Amendment and should have been examined with claims 1-13. By this Amendment, applicants have amended claims 3, 9, 11, and 12. Applicants maintain that no issue of new matter is raised by these amendments. Accordingly, applicants respectfully request that this Amendment be entered. Upon entry of this Amendment, claims 1-17 as amended will be pending in this application and ready for examination.

Applicants note that in the Office Action the Examiner indicates that claims 1, 2, 4-8, 10 and 13 are allowed. Claims 3, 9, 11, and 12 dependent from allowed claims are rejected for certain indefinite recitation. Applicants have herein amended claims 3, 9, 11, and 12 to overcome the Examiner's rejection and maintain that these claims as amended should also be allowed. Applicants further maintain that claims 14-17 should also be deemed allowable.

Objection to the Specification

The Examiner objected to the Specification as lacking a reference to the prior filed applications. In response, applicants have amended the subject specification to insert a reference to the prior filed PCT application as well as the foreign priority document at the beginning of the specification. Accordingly, applicants maintain that the Examiner's objection has been obviated and this ground of objection should be withdrawn.

Rejection Under 35 U.S.C. 112, Second Paragraph

The Examiner rejected claims 3, 9, 11, and 12 under 35 U.S.C. 112, second paragraph, as indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. Specifically, the Examiner rejected claim 3 for reciting "18-

Applicants: Salvador Puig et al.

Serial No.: 10/566,413

Filing Date: January, 30, 2006

Page 8 of 8

corona-6-ether; claim 9 for reciting "tresylate"; and claims 11 and 12 for reciting "trithyl (triphenylmethylo)".

In response, applicants have amended claims 3, 9, 11, and 12. Claim 3 has been amended to recite "18-crown-6-ether" and maintain that the phrase "18-corona-6-ether" is an obvious translation error when the Spanish application was translated into English. Claim 9 has been amended to recite "2,2,2-trifluoro-ethane-sulfonate" instead of "tresylate" which is the informal name of 2,2,2-trifluoro-ethane-sulfonate as evidenced by the attached Abstract of Journal of Radio analytical and Nuclear Chemistry, Vol. 251, No 3 (2002). Claims 11 and 12 have been amended to recite trityl (triphenylmethyl) instead of trithyl (triphenylmethylo) and maintain that this is an typographical error. Accordingly, applicants maintain that these amendments obviate the Examiner's ground of rejection and respectfully request that the Examiner reconsider and withdraw this rejection.

Reconsideration and allowance of all pending claims herein are respectfully requested.

Respectfully submitted,

July 6, 2009

Aude Gerspacher

Registration No. \$7,919

Cozen O'Connor 250 Park Avenue

New York, New York 10177-0030

Telephone: 212.986.1116

The nucleophilic substitution reaction for [18F]fluoride-ion on the series of N6-benzoyl-2',3'-isopropylideneadenosine-5'-sulfonates

Sz. Lehel, G. Horváth, I. Boros, T. Márián, L. Trón*

Positron Emission Tomograph Centre, University of Debrecen, H-4012 Debrecen, Nagyerdei krt 98, Hungary (Received January 4, 2001)

The reaction of the nca [18F]fluoride ion was investigated toward a series of N⁶-benzoyl 2',3'-isopropylidene-adenosine-5'-sulfonates including the methane-(mesylate), p-toluene-(tosylate), p-nitro-benzene-(nosylate)- and 2,2,2-trifluoro-ethane-sulfonate (tresylate) derivatives under usual nucleophilic substitution conditions. In these reactions cyclisation of the title compounds was observed whilst the radiofluorination took place only with low yield. The fluorine-18 uptake was found to be 1.17% for mesylate, 1.46% for tosylate, 0.99% for nosylate and 0.40% for tresylate under the conditions applied.